
    
      To carry out this study, 24 moderate CD patients will be enrolled in a safety phase 2a study.
      CD patients will be included after intestinal resection surgery or in moderate Crohn's
      Disease (CD). Drug therapy will consisted in 3 injections of 100 Âµg of P28GST within 3 months
      (one injection per month). The main objective of this study is to follow-up monthly rate and
      seriousness of adverse events during one year. Secondary objectives are to control
      immunologic and inflammatory blood and tissue markers, appearance or not of a clinical
      recurrence assessed by CDAI (Crohn Disease Activity Index).
    
  